Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients

Sign up to the Linkers System and receive email notifications

Access to new sales channels where leading manufacturers can directly access the database and engage with prospective partner companies.


What is Linkers?

Linkers is a system where SMEs, Startups and Academia can directly respond to the needs of major Japanese manufacturers.


Find out more via the hyperlink above!

Two companies, TraitSeq and PfBIO, that originated from research carried out at Norwich Research Park, have announced significant funding that will help them with the next stages of their development. Both were successful in securing grants of around £100,000 from Innovate UK’s Launchpad programme. Only seven companies in the East of England received these grants where the focus is to develop new activity in agri-tech and food technology and drive innovation in food production and sustainability.

T-Therapeutics appoints Dr David Hung as Chairman

Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development of the company’s pipeline of TCR-based immuno-oncology drugs

12 June 2024; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble TCR therapeutics targeting cancer and autoimmune indications, today announces the appointment of biopharma industry veteran Dr David Hung as Chairman of its Board of Directors.

New space recognises the need for more cost-effective bench space and flexible agreements for startups and spinouts 

Sandwich, Kent, UK / 10th June 2024 / Discovery Park, Kent’s thriving life science community, has opened the doors to CoLab, a new shared lab facility. In partnership with Canterbury Christ Church University, CoLab has been specially designed for early-stage life science businesses, providing flexible bench space in a collaborative coworking environment.

Your Local Laboratory For Rapid Whole Plasmid Nanopore Sequencing Results

Located in Cambridge, Source Genomics is a leading provider of genomic services, processing all samples within our UK laboratory. With the introduction of our new SpeedREAD™ data delivery system for Whole Plasmid Nanopore Sequencing, we now offer unrivaled turnaround times.

Why Choose SpeedREAD™?

Milestone payment follows successful target identification and validation in separate project under same collaboration

Cambridge, UK, 03 June 2024: PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies, to transform patients’ lives.

CAMBRIDGE and NEWCASTLE, UK, 03 June 2024: DefiniGEN Ltd., and Atelerix Ltd., today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US. The agreement between the companies combines DefiniGEN’s mechanistically relevant iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which prevents loss of function and enables even sensitive samples to remain stable at ambient temperatures for up to two weeks.

The Femtech & Women’s Health edition of ‘Discovery Spark’ champions early stage businesses working to close the gender health gap

Sandwich, Kent, UK / 30th May 2024 / Discovery Park, Kent’s thriving life science and innovation community, announced the selection of 11 promising start-ups in FemTech & Women’s Health to join Discovery Spark, their growth and support programme for early stage businesses.